Logo

Roche Reports Updated OS Data of Tecentriq + Avastin in P-III IMbrave150 Study for Unresectable HCC

Share this

Roche Reports Updated OS Data of Tecentriq + Avastin in P-III IMbrave150 Study for Unresectable HCC

Shots:

  • The approval is based on P-III IMbrave150 study involves assessing of Tecentriq (1200mg) + Avastin (15 mg/kg) on day 1 of each 21-day cycle vs sorafenib (400mg- bid) on days 1-21 of each 21-day cycle in 501 patients in a ratio (2:1) with unresectable HCC- prior not treated with systemic therapies
  • Results: @median follow-up of 15.6mos.- 34% reduction in OS; m-OS (19.2 vs 13.4mos.); mPFS (6.9 vs 4.3mos.). In Chinese population- m-OS (24.0 vs 11.4mos.)
  • Tecentriq + Avastin is an approved therapy across the globe- including in the US- China- Japan and the EU- for people with unresectable HCC and is recommended in many clinical practice guidelines globally

 ­ Ref: Roche | Image: Roche 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions